Cart
sales@molnova.com
Ervogastat
CAS No. 2186700-33-2
Ervogastat( PF-06865571 )
Catalog No. M23988 CAS No. 2186700-33-2
Ervogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 318 | In Stock |
|
| 5MG | 307 | In Stock |
|
| 10MG | 512 | In Stock |
|
| 25MG | 826 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | 1479 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameErvogastat
-
NoteResearch use only, not for human use.
-
Brief DescriptionErvogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor.
-
DescriptionErvogastat is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
-
In Vitro——
-
In Vivo——
-
SynonymsPF-06865571
-
PathwayMetabolic Enzyme/Protease
-
TargetTransferase
-
RecptorDGAT2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2186700-33-2
-
Formula Weight407.42
-
Molecular FormulaC21H21N5O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:120mg/ml(294.54mM, need ultrasonic)
-
SMILESO=C(C1=CN=C(C2=CC(OC3=NC=CC=C3OCC)=CN=C2)N=C1)N[C@@H]4COCC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS
molnova catalog
related products
-
OU749
OU749 is a γ-glutamyl transferase (GGT) inhibitor with an intrinsic Ki of 17.6 μM.
-
CP-609754
CP-609754 shows selective inhibition of farnesyltransferase.
-
CBHcy
CBHcy is a dual-substrate analogue, a specific BHMT inhibitor that causes betaine-homocysteine S-methyltransferase (BHMT) to adopt the same conformation as the ternary complex, potentially inducing the development of cysteinemia.
